An Open-label, Randomized Crossover Study to Obtain a Preliminary Estimate of the Bioavailability of Atazanavir and Cobicistat When Administered in an Age-appropriate Fixed-Dose Combination Formulation Compared With Coadministration of the Age-appropriate Atazanavir and Cobicistat Individual Formulations and to Assess Preliminary Palatability/Acceptability in Healthy Adults
Latest Information Update: 28 Nov 2021
At a glance
- Drugs Atazanavir/cobicistat (Primary) ; Atazanavir; Cobicistat
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 18 Nov 2021 Status changed from not yet recruiting to completed.
- 17 Feb 2020 New trial record